Press Releases

Press Releases

Date Title Files

Jun 03, 2019

Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting

Jun 01, 2019

Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting

May 23, 2019

Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business

May 08, 2019

Dynavax Announces First Quarter 2019 Financial Results

May 02, 2019

Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] in Adults With End-Stage Renal Disease

Apr 25, 2019

Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8

Apr 18, 2019

Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019

Apr 02, 2019

Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting

Apr 01, 2019

Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models

Mar 28, 2019

Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults